Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy

Cancer Discovery

Volumn 5, Issue 12, 2015, Pages 1282-1295

  Sotillo, Elena ^a   Barrett, David M ^a   Black, Kathryn L ^a   Bagashev, Asen ^a   Oldridge, Derek ^a   Wu, Glendon ^a,b   Sussman, Robyn ^a   Lanauze, Claudia ^a,b   Ruella, Marco ^b   Gazzara, Matthew R ^b   Martinez, Nicole M ^b   Harrington, Colleen T ^a,b   Chung, Elaine Y ^a   Perazzelli, Jessica ^a   Hofmann, Ted J ^a   Maude, Shannon L ^a   Raman, Pichai ^a   Barrera, Alejandro ^b   Gill, Saar ^b,c   Lacey, Simon F ^c   Melenhorst, Jan J ^c   Allman, David ^b   Jacoby, Elad ^d   Fry, Terry ^d   Mackall, Crystal ^d   Barash, Yoseph ^b   Lynch, Kristen W ^b   Maris, John M ^a   Grupp, Stephan A ^a   Thomas Tikhonenko, Andrei ^a,b   more..

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; SMALL INTERFERING RNA; TISAGENLECLEUCEL T; EPITOPE; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; MESSENGER RNA; PROTEIN BINDING; RNA BINDING PROTEIN; SERINE ARGININE RICH SPLICING FACTOR; SRSF3 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALTERNATIVE RNA SPLICING; ARTICLE; B CELL LEUKEMIA; CD19 GENE; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DEGLYCOSYLATION; DNA EXTRACTION; DNA TRANSFECTION; ENHANCER REGION; FLOW CYTOMETRY; GENE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; METHYLATION; MULTIPLEX POLYMERASE CHAIN REACTION; POINT MUTATION; PROMOTER REGION; RADIOACTIVITY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING; B LYMPHOCYTE; CELL MEMBRANE; DNA SEQUENCE; EXON; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MUTATION; PATHOLOGY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; RECURRENT DISEASE;

ALTERNATIVE SPLICING; ANTIGENS, CD19; B-LYMPHOCYTES; CELL MEMBRANE; EPITOPES; EXONS; HUMANS; IMMUNOTHERAPY; MUTATION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; RECURRENCE; RNA, MESSENGER; RNA-BINDING PROTEINS; SEQUENCE ANALYSIS, DNA; SERINE-ARGININE SPLICING FACTORS; TRANSCRIPTION, GENETIC;

EID: 84947984588     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-1020     Document Type: Article

References (49)

1. Roberts KG, Mullighan CG. Genomics in acute lymphoblastic leukaemia: insights and treatment implications. Nat Rev Clin Oncol 2015;12:344-57
2. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33
3. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. SciTransl Med 2011 3:95ra73
4. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia . N Engl J Med 2014;371:1507-17
5. Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase IItrial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia . J Clin Oncol 2014;32:4134-40
6. Otero DC, Rickert RC. CD19 function in early and late B cell development. II. CD19 facilitates the pro-B/pre-B transition. J Immunol 2003;171:5921-30
7. Otero DC, Anzelon AN, Rickert RC. CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals. J Immunol 2003;170:73-83
8. Wang Y, Brooks SR, Li X, Anzelon AN, Rickert RC, Carter RH. The physiologic role of CD19 cytoplasmic tyrosines. Immunity 2002;17:501-14
9. Del Nagro CJ, Otero DC, Anzelon AN, Omori SA, Kolla RV, Rickert RC. CD19 function in central and peripheral B-cell development. Immunol Res 2005;31:119-31
10. Chung EY, Psathas JN, Yu D, Li Y, Weiss MJ, Thomas-Tikhonenko A. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J Clin Invest 2012;122:2257-66
11. Rickert RC, Rajewsky K, Roes J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 1995;376:352-5
12. Poe JC, Minard-Colin V, Kountikov EI, Haas KM, Tedder TF. A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice. J Immunol 2012;189:2318-25
13. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-18
14. Maquat LE. Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. Nat Rev Mol Cell Biol 2004;5:89-99
15. Kozmik Z, Wang S, Dorfler P, Adams B, Busslinger M. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol Cell Biol 1992;12:2662-72
16. Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Wheeler DL. GenBank: update. Nucleic Acids Res 2004;32:D23-6
17. Gazzara MR, Vaquero-Garcia J, Lynch KW, Barash Y. In silico to in vivo splicing analysis using splicing code models. Methods 2014;67:3-12
18. Barash Y, Vaquero-Garcia J, Gonzalez-Vallinas J, Xiong HY, Gao W, Lee LJ, et al. AVISPA: a web tool for the prediction and analysis of alternative splicing. Genome Biol 2013;14:R114
19. Dreyfuss G, Kim VN, Kataoka N. Messenger-RNA-binding proteins and the messages they carry. Nat Rev Mol Cell Biol 2002;3:195-205
20. Anko ML, Muller-McNicoll M, Brandl H, Curk T, Gorup C, Henry I, et al. The RNA-binding landscapes of two SR proteins reveal unique functions and binding to diverse RNA classes. Genome Biol 2012;13:R17
21. Psathas JN, Doonan PJ, Raman P, Freedman BD, Minn AJ, Thomas-Tikhonenko A. The Myc-miR-17–92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. Blood 2013;122: 4220–9
22. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. ESEfinder:A web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003;31:3568-71
23. Ray D, Kazan H, Cook KB, Weirauch MT, NajafabadiHS, LiX, et al. A compendium of RNA-binding motifs for decoding gene regulation. Nature 2013;499:172-7
24. Nicholson IC, Lenton KA, Little DJ, Decorso T, Lee FT, Scott AM, et al. Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. Mol Immunol 1997;34:1157-65
25. Zola H, MacArdle PJ, Bradford T, Weedon H, Yasui H, Kurosawa Y. Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol Cell Biol 1991;69(Pt 6):411-22
26. Yu D, Allman D, Goldscmidt M, Atchison M, Monroe JG, Thomas- Tikhonenko A. Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/ reactivation of the EBF/Pax5 pathway. Blood 2003;101:1950-5
27. Cozma D, Yu D, Hodawadekar S, Azvolinsky A, Grande S, Tobias JW, et al. B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling. J Clin Invest 2007;117:2602-10
28. van Zelm MC, Smet J, Adams B, Mascart F, Schandene L, Janssen F, et al. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest 2010;120:1265-74
29. Shoham T, Rajapaksa R, Kuo CC, Haimovich J, Levy S. Building of the tetraspanin web: distinct structural domains of CD81 function in different cellular compartments. Mol Cell Biol 2006;26:1373-85
30. Depoil D, Fleire S, Treanor BL, Weber M, Harwood NE, Marchbank KL, et al. CD19 is essential for B cell activation by promoting B cell receptor-antigen microcluster formation in response to membranebound ligand. Nat Immunol 2008;9:63-72
31. Buchner M, Muschen M. Targeting the B-cell receptor signaling pathway in B lymphoid malignancies. Curr Opin Hematol 2014;21:341-9
32. Hnilicova J, Stanek D. Where splicing joins chromatin. Nucleus 2011;2:182-8
33. Iannone C, Valcarcel J. Chromatin’s thread to alternative splicing regulation. Chromosoma 2013;122:465-74
34. Naftelberg S, Schor IE, Ast G, Kornblihtt AR. Regulation of alternative splicing through coupling with transcription and chromatin structure. Annu Rev Biochem 2015;84:165-98
35. Brown SJ, Stoilov P, Xing Y. Chromatin and epigenetic regulation of pre-mRNA processing. Hum Mol Genet 2012;21:R90-R6
36. Pradeepa MM, Sutherland HG, Ule J, Grimes GR, Bickmore WA. Psip1/Ledgf p52 binds methylated histone H3K36 and splicing factors and contributes to the regulation of alternative splicing. PLoS Genet 2012;8:e1002717
37. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012;44:47-52
38. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia . Nature 2011;478:64-9
39. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011;480:387-90
40. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape. Curr Opin Immunol 2014;27:16-25
41. Barrett DM, Seif AE, Carpenito C, Teachey DT, Fish JD, June CH, et al. Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. Blood 2011;118:e112-e7
42. Costes SV, Daelemans D, Cho EH, Dobbin Z, Pavlakis G, Lockett S. Automatic and quantitative measurement of protein-protein colocalization in live cells. Biophys J 2004;86:3993-4003
43. Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 2014;123:2343-54
44. Lynch KW, Weiss A. A model system for activation-induced alternative splicing of CD45 pre-mRNA in T cells implicates protein kinase C and Ras. Mol Cell Biol 2000;20:70-80
45. Rothrock CR, House AE, Lynch KW. HnRNP L represses exon splicing via a regulated exonic splicing silencer. EMBO J 2005;24:2792-802
46. Lynch KW, Maniatis T. Assembly of specific SR protein complexes on distinct regulatory elements of the Drosophila doublesex splicing enhancer. Genes Dev 1996;10:2089-101
47. Mallory MJ, Jackson J, Weber B, Chi A, Heyd F, Lynch KW. Signaland development-dependent alternative splicing of LEF1 in T cells is controlled by CELF2. Mol Cell Biol 2011;31: 2184–95
48. Sotillo E, Laver T, Mellert H, Schelter JM, Cleary MA, McMahon S, et al. Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene 2011;30:2587-94
49. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013;29:15-21.